Other studies showed a decrease in the expression of the Galectin-3 in breast, ovary, prostate cancers, advanced uterine adenocarcinoma, basal cell of the skin, epithelial skin, and malignant salivary gland neoplasms, compared to the corresponding normal tissue (reviewed by 23, 26). The gene discussed is LGALS3; the disease is prostate cancer.